Ask about this productRelated genes to: LIMD2 antibody
- Gene:
- LIMD2 NIH gene
- Name:
- LIM domain containing 2
- Previous symbol:
- -
- Synonyms:
- MGC10986
- Chromosome:
- 17q23.3
- Locus Type:
- gene with protein product
- Date approved:
- 2006-01-24
- Date modifiied:
- 2014-11-19
Related products to: LIMD2 antibody
Related articles to: LIMD2 antibody
- Overexpression of LIMD2 (LIM domain-containing protein 2) promotes cancer progression by enhancing cell migration and suppressing apoptosis. Here, we report a computational pipeline for the de novo design of LIMD2-targeting peptide inhibitors. We identified three key binding sites on LIMD2 that form a steric triangle and used RFdiffusion exclusively for geometry-constrained backbone generation within this predefined cavity, a step that does not involve affinity scoring but ensures spatial compatibility prior to sequence design. To enhance structural stability, we constrained sequence design to α-helical peptides using ProteinMPNN. Predicted binding affinities between LIMD2 and designed peptides were evaluated via the deep learning model PEP-PPI, and the top 100 candidates were structurally modeled and refined using Rosetta Build module and FlexPepDock. The top 20 peptides were subjected to toxicity prediction, and finally 17 peptides without toxicity were synthesized and experimentally validated via isothermal titration calorimetry (ITC), with three showing measurable binding, and the best displaying an affinity of 93.7 μM. Top peptides (MSPEERAALAR) exhibited inhibitory effects on tumor cell proliferation in in-vitro assays using triple-negative breast cancer cell lines MDA-MB-231 and MDA-MB-468, highlighting their potential as tumor inhibitors. In further, we analyzed the binding mechanism of the peptide inhibitors against LIMD2, revealing key binding residue within peptide, highlighting the designing binding craft as can identify key sites within peptide to bind with the target. This study presents a robust strategy for de novo functional peptide design and identifies LIMD2-targeting peptides with potential for further antitumor drug development. - Source: PubMed
Publication date: 2026/03/23
Huang QiuyanYu YushuaiHuang KaiZhu ZhengwenWang XinglongSong Chuangui - Clear cell renal cell carcinoma (ccRCC) is characterized by abundant infiltration of CD8⁺ T cells; however, the clinical benefit from immune checkpoint inhibitors (ICI) remains limited. To clarify this paradox, we systematically investigated the functional states of CD8⁺ T cells in ccRCC, with a particular focus on exhaustion-associated subsets and their potential link to ICI responsiveness. By integrating six publicly available bulk and single-cell RNA sequencing datasets with independent institutional validation cohorts, we found that the majority of tumor-infiltrating CD8⁺ T cells exhibited an exhausted phenotype, characterized by elevated expression of canonical exhaustion markers. Importantly, we identified CD8⁺ T cells with high LIM domain-containing protein 2 (LIMD2) expression that co-express canonical exhaustion markers and are enriched in ICI responders. Single-cell transcriptomic analyses further supported markedly increased LIMD2 expression within CD8⁺ Tex cells from patients achieving clinical benefit. Multiplex immunofluorescence showed LIMD2 protein predominantly localized to CD8A⁺ T cells, co-expressed with exhaustion markers, and significantly enriched in tumor tissues of responders. Collectively, these findings indicate that CD8⁺ Tex cells with high LIMD2 expression are associated with ICI responses in ccRCC, positioning LIMD2 as a candidate predictive biomarker to refine patient stratification and inform immunotherapy optimization. - Source: PubMed
Publication date: 2025/12/04
Zhang JunfengPeng QingyanXiang XiaolongLiu FuzhongJiang XiangdongNie HongweiBi XingPan TingLi KailingChen PengYuan ShuaiChen Su - Atrazine (ATZ), a frequently used herbicide, has well-documented toxicities in various organisms, yet its specific impact on skeletal muscle remains largely uncharted. Here, we found that ATZ inhibited myotube formation in C2C12 myoblasts and decreased both body weight and the cross-sectional areas of type IIA, IIB, and IIX myofibers in mice. Furthermore, ATZ drove muscle fiber shifting from mixed oxidative/glycolytic type IIA to fast-glycolytic type IIB, reduced satellite stem cell abundance, and contributed to excessive lipid accumulation. Mechanistically, transcriptomic analyses indicated that ATZ triggered inflammation, oxidative stress, adipogenesis, and protein degradation, as evidenced by elevated ROS, augmented NF-κB pathway, and disrupted protein homeostasis. By integrating transcriptomic data with eQTL and grip strength GWAS findings from 454,473 individuals, and applying Mendelian randomization and Bayesian colocalization analyses, we pinpointed 14 genes that were both dysregulated by ATZ and causally linked to muscular strength. Further interrogation of single-cell/nucleus RNA-sequencing data revealed cell type-specific patterns of 10 reasonable causal genes (Jund, Limd2, Ppm1j, Procr, Cdo1, Irs1, Kif1b, Nav1, Nexn, Peak1), highlighting the multifaceted cellular processes underlying ATZ-inflicted muscle damage. Notably, Morroniside, with anti-inflammatory and antioxidant properties, rescued several potential therapeutic targets (Limd2, Jund, Irs1, Kif1b, Peak1, Nav1) and C2C12 myotubes from ATZ-induced atrophy. Collectively, our study sheds light on the effects and molecular underpinnings of ATZ-mediated skeletal muscle toxicity and brings forward viable therapeutic targets and strategy. The multi-omics approach offers a robust framework for translating findings from cell/animal models to human relevance in toxicological research. - Source: PubMed
Publication date: 2025/09/12
Tao JianguoGu JiaxuanMiao MaomaoChen Guo-BoHu XueqinYao SaiWu OuXu TaotaoLuo HuanJin HongtingWu ChengliangTong PeijianRuan HongfengYi XiangjiaoZheng Hou-Feng - LIM domain-containing protein 2 (LIMD2) is known to promote metastasis in several cancers. However, its role and underlying mechanisms in colon cancer remain unclear. This study focused on investigating the prognostic value, functional impact, and molecular mechanisms of LIMD2 in colon cancer. - Source: PubMed
Publication date: 2025/08/14
Wang JianjunCai FengjuanLiu GuodongZhang JingtaoLi DongdongCai YujieWang YuXu WanjunWang XiaoyanLi Xiaomin - Breast cancer (BC) poses a serious threat to human health. Disulfidptosis is a recently discovered form of cell death associated with cancer prognosis and progression. However, the relationship between BC and disulfidptosis remains unclear. - Source: PubMed
Publication date: 2023/12/05
Chen XiongHu GuohuangYu Qianle